PDCD1 and non-small cell lung carcinoma: Immune checkpoint antibodies block the PD-1 pathway by targeting PD-L1 or PD-1 and have shown good clinical efficacy in treating various malignancies, including NSCLC, in which KRAS/RAF mutations are the common driving events (Brahmer et al., 2015).